Author: Bihar Say | Amrita | A Bold Statement from Patna on the Global Health Stage The moment felt electric: a senior physician from Patna walked into the
The moment felt electric: a senior physician from Patna walked into the room in Atlanta and declared that a 70-year-old generic antibiotic might soon shift the dynamics of STI prevention. At IDWeek 2025, a global infectious-disease gathering, he presented emerging evidence that using Doxycycline after sexual exposure—or in some trials before high-risk contact—can sharply cut rates of bacterial STIs like syphilis and chlamydia. According to his summary of international data, reductions of 80% or more are becoming plausible.
In fact, one real-world study found reductions of 86.4% for syphilis and 89.7% for chlamydia when doxycycline post-exposure prophylaxis (doxy-PEP) was used.
Yet, as the Patna physician emphasised, this is not a silver bullet. He stressed the need for medical supervision, regular STI testing, and antibiotic resistance monitoring. After all, the global agency World Health Organization (WHO) in 2025 explicitly began developing guidelines on doxycycline prophylaxis for STIs.
Emerging Data.
Several studies now support the idea that doxycycline taken within 72 hours of unprotected sex can dramatically reduce certain bacterial STI risks. In one randomized trial among men who have sex with men (MSM) and transgender women, incidence of syphilis, chlamydia and gonorrhoea dropped significantly. Infectious Diseases Society of America Another real-world dataset supported these findings.
Key Findings:
Reduction in syphilis and chlamydia cases reached up to ~80-90% in some cohorts.
Effect on gonorrhoea is more modest and currently under question.
The WHO is reviewing and considering formal guideline development for doxycycline prophylaxis in STIs.
Why It Matters.
In many countries—including India—the burden of bacterial STIs remains high, yet prevention tools have stagnated. Here, an age-old antibiotic repurposed for prophylaxis could be a game-changer. Moreover, having a physician from Patna bring these results to a major international conference underscores how local expertise is now emerging as global voice.
Diwakar Tejaswi (Senior Physician, Patna) took the stage in Atlanta and framed the data through a global-local lens. He argued that while the trials were conducted in Western countries and among high-risk groups, the findings have relevance for India as well—especially for populations that face educational or access barriers.
Importantly, Dr Tejaswi stressed responsibility:
“While doxycycline shows promise, responsible usage and ongoing research are essential to prevent resistance and ensure patient safety.”
That message resonates particularly in India, where antibiotic misuse remains high and resistance trends are well-documented.
Potential Pathways:
Indian clinicians could consider doxy-PEP for high-risk individuals under supervised protocols.
Public-health authorities might integrate doxycycline prophylaxis into broader STI‐control guidelines if further Indian trials validate efficacy and safety.
But Important Caveats:
Antibiotic resistance is a real threat. Studies show that tetracycline-class resistance genes increased among microbes exposed to doxy-PEP.
Gonorrhoea remains hard to prevent via doxy-PEP and demands other strategies.
Any rollout must include STI testing, resistance surveillance, and patient education.
With the WHO gearing up to issue formal guidelines on doxycycline prophylaxis in STIs, global public-health practice may soon shift. Meanwhile, the presentation at IDWeek 2025 by a Patna physician connects global research to Indian relevance, potentially opening doors for local research, policy discussions and public-health dialogue.
Don’t miss future updates and deep-dives like this. Follow www.biharsay.com for regular insights, and join our 13,000+ strong global community now! Bihar Say is Bihar’s leading apolitical media and storytelling platform, reshaping the state’s image through impactful stories on culture, business and grassroots change. Its flagship podcast and video series, BiharCast, spotlight changemakers, traditions and rising voices from the heart of Bihar.
